Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enlivex Therapeutics Ltd. - Ordinary Shares (NQ:ENLV)

1.215 +0.035 (+2.97%)
Streaming Delayed Price Updated: 12:18 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enlivex Therapeutics Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Nasdaq Jumps 250 Points; Crude Oil Down 1%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday. The Dow traded up 0.18% to 38,532.50 while the NASDAQ rose 1.63% to 16,433.83.... 
Via Benzinga
Topics Stocks
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. 
Via Benzinga
Dow Dips 100 Points; CarMax Earnings Miss Views
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Thursday. 
Via Benzinga
Topics Earnings Stocks
Nasdaq Gains Over 50 Points; US Producer Prices Increase In March
U.S. stocks traded mostly higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.03% to 38,472.80 while the NASDAQ rose 0.40% to 16,234.94.... 
Via Benzinga
Topics Stocks
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
ENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023
ENLV stock results show that Enlivex Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
Via ACCESSWIRE
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals
Via ACCESSWIRE
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
From MediWound Ltd.
Via GlobeNewswire
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth... 
Via Benzinga
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. 
Via Benzinga
Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740. 
Via Benzinga
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
From Enlivex Therapeutics Ltd
Via GlobeNewswire
This Biotech Is Bringing Balance To The Body – How Homeostasis Is Critical To Fighting Everything From Sepsis To Cancer
Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was recently a guest on Benzinga’s All-Access. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.